| Dr Adam Joseph Pascoe, MD | |
|
1 Guthrie Sq, Sayre, PA 18840 | |
| (570) 887-2493 | |
| (570) 887-3254 |
| Full Name | Dr Adam Joseph Pascoe |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Occupational Medicine |
| Location | 1 Guthrie Sq, Sayre, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972846723 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083X0100X | Preventive Medicine - Occupational Medicine | R3860 (Kentucky) | Secondary |
| 2083X0100X | Preventive Medicine - Occupational Medicine | MD465457 (Pennsylvania) | Primary |
| Entity Name | Guthrie Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962451153 PECOS PAC ID: 6002728656 Enrollment ID: O20040301000571 |
News Archive
Medgenics is pleased to announce that one of the patients, who was treated with the Company's EPODURE tissue Biopumps almost 11 months ago, continues to be effectively treated for anemia without a single erythropoietin (EPO) injection. This patient (#2) was dependent on frequent injections of the therapeutic protein (EPO) for the 18 months prior to receiving a single administration of 3 tiny EPODURE tissue Biopumps in the Company's phase I/II anemia trial in Israel.
IMRIS Inc. (TSX: IM) ("IMRIS" or the "Company") today announced that Health Canada has issued a medical device licence for the Company's IMRX system permitting IMRIS to market its newest products, IMRISNV and IMRIScardio in Canada.
The old men live in cramped spaces and breathe the same ventilated air. Many are frail, laboring with heart disease, liver and prostate cancer, tuberculosis, dementia. And now, with the coronavirus advancing through their ranks, they are falling one after the next.
Kansas will send back its $31.5 million Early Innovator Grant to the Department of Health and Human Services, which would have helped pay for the development of the state's online insurance exchange. Gov. Sam Brownback said he was returning the money because of doubts that the federal government would be able to maintain its promised future payments.
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Adam Joseph Pascoe, MD 1 Guthrie Sq, Sayre, PA 18840-1625 Ph: (570) 888-5858 | Dr Adam Joseph Pascoe, MD 1 Guthrie Sq, Sayre, PA 18840 Ph: (570) 887-2493 |
News Archive
Medgenics is pleased to announce that one of the patients, who was treated with the Company's EPODURE tissue Biopumps almost 11 months ago, continues to be effectively treated for anemia without a single erythropoietin (EPO) injection. This patient (#2) was dependent on frequent injections of the therapeutic protein (EPO) for the 18 months prior to receiving a single administration of 3 tiny EPODURE tissue Biopumps in the Company's phase I/II anemia trial in Israel.
IMRIS Inc. (TSX: IM) ("IMRIS" or the "Company") today announced that Health Canada has issued a medical device licence for the Company's IMRX system permitting IMRIS to market its newest products, IMRISNV and IMRIScardio in Canada.
The old men live in cramped spaces and breathe the same ventilated air. Many are frail, laboring with heart disease, liver and prostate cancer, tuberculosis, dementia. And now, with the coronavirus advancing through their ranks, they are falling one after the next.
Kansas will send back its $31.5 million Early Innovator Grant to the Department of Health and Human Services, which would have helped pay for the development of the state's online insurance exchange. Gov. Sam Brownback said he was returning the money because of doubts that the federal government would be able to maintain its promised future payments.
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
› Verified 8 days ago
Aiysha R Ansari, M.D. Preventive Medicine Medicare: Medicare Enrolled Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-887-2493 Fax: 570-887-3254 | |
Dr. Ian Phillip Snider, DO Preventive Medicine Medicare: Medicare Enrolled Practice Location: 317 W Lockhart St, Sayre, PA 18840 Phone: 570-887-3920 Fax: 570-887-3035 | |
Dr. Theodore Frederick Them, MD Preventive Medicine Medicare: Medicare Enrolled Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-5858 |